Is NCT06528691 recruiting in Memphis, TN?

Yes, NCT06528691 is currently recruiting participants at its Memphis, TN location. This high grade glioma clinical trial is actively enrolling qualified participants.

How do I join the high grade glioma clinical trial in Memphis?

To join this clinical trial in Memphis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Memphis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

High Grade Glioma Clinical Trial in Memphis, TN

Who Can Participate

Inclusion Criteria

Screening Phase

Age from birth to age \<3 years at the time of diagnosis (date of surgical resection/biopsy)

Participant with presumed newly diagnosed tumor in the supratentorial compartment

Patient must have measurable disease based on RAPNO criteria

≤84 days since surgery (resection or biopsy)

Available tumor tissue for central review

Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria

Screening Phase

Previous exposure to cytotoxic chemotherapy or radiotherapy Inclusion Criteria: COHORT 1

Patients must be \<3 years of age at the time of diagnosis (date of surgical resection/biopsy)

High-grade glioma (World Health Organization \[WHO\] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

Patients must have measurable disease as defined by RAPNO criteria

Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

≤28 days since study screening

Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

Neurologic deficits must have been stable for at least 7 days prior to study enrollment

Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)

Absolute neutrophil count \>1,000/µL

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)

Bilirubin ≤ 1.5 x ULN

Adequate renal function as defined by the following age-based serum creatinine concentrations:

0 to \<1 year: 0.5 mg/dL

1 to \<2 years: 0.6 mg/dL

2 to 3 years: 0.8 mg/dL

Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) \>50%

Screening and enrollment consents signed

Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures Inclusion Criteria: COHORT 2

Patients must be \<3 years of age at the time of diagnosis (date of surgical resection/biopsy)

CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

Patients must have measurable disease as defined by RAPNO criteria

Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

≤28 days since study screening

Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

Neurologic deficits must have been stable for at least 7 days prior to study enrollment.

Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);

Absolute neutrophil count \>1,000/µL.

ALT and ALT ≤2.5x the upper limit of normal (ULN)

Bilirubin ≤ 1.5 x ULN

Adequate renal function as defined by the following age-based serum creatinine concentrations:

0 to \<1 year: 0.5 mg/dL

1 to \<2 years: 0.6 mg/dL

2 to 3 years: 0.8 mg/dL

Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF \>50%

Screening and enrollment consents signed

Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures Exclusion Criteria: COHORT 1 AND 2

Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history

History of recent (3 months) symptomatic congestive heart failure

Known active, uncontrolled infection (bacterial, fungal, or viral)

Receiving enzyme inducing antiepileptic drugs (EIAEDs)

Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation

Receiving another investigational agent concurrently

Surgery within 2 weeks prior to treatment enrollment

Patients with known hypersensitivity to excipients of the investigational medicinal product

Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption

Inability to take medication enterally

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT06528691) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

High Grade Glioma Treatment Options in Memphis, TN

If you're searching for high grade glioma treatment options in Memphis, TN, this clinical trial (NCT06528691) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced high grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all high grade glioma clinical trials near you to find additional studies recruiting in your area.

High Grade Glioma Clinical Trial in Memphis, TN

Expert Care in Memphis

IRB Approved

No-Cost Care

Apply for This Memphis Location

Why Participate?

Simple Process

About This High Grade Glioma Study in Memphis